These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1049 related items for PubMed ID: 15304466

  • 1. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
    Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators.
    JAMA; 2004 Aug 11; 292(6):696-703. PubMed ID: 15304466
    [Abstract] [Full Text] [Related]

  • 2. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
    Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators.
    JAMA; 2003 Feb 19; 289(7):853-63. PubMed ID: 12588269
    [Abstract] [Full Text] [Related]

  • 3. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
    Feldman DN, Wong SC, Bergman G, Minutello RM.
    J Invasive Cardiol; 2009 Jun 19; 21(6):258-63. PubMed ID: 19494400
    [Abstract] [Full Text] [Related]

  • 4. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
    Saw J, Lincoff AM, DeSmet W, Betriu A, Rutsch W, Wilcox RG, Kleiman NS, Wolski K, Topol EJ, REPLACE-2 Investigators.
    J Am Coll Cardiol; 2004 Sep 15; 44(6):1194-9. PubMed ID: 15364319
    [Abstract] [Full Text] [Related]

  • 5. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
    Cohen DJ, Lincoff AM, Lavelle TA, Chen HL, Bakhai A, Berezin RH, Jackman D, Sarembock IJ, Topol EJ.
    J Am Coll Cardiol; 2004 Nov 02; 44(9):1792-800. PubMed ID: 15519009
    [Abstract] [Full Text] [Related]

  • 6. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
    Feldman DN, Wong SC, Gade CL, Gidseg DS, Bergman G, Minutello RM.
    Am Heart J; 2007 Oct 02; 154(4):695-701. PubMed ID: 17892994
    [Abstract] [Full Text] [Related]

  • 7. Bivalirudin in PCI: an overview of the REPLACE-2 trial.
    Maroo A, Lincoff AM.
    Semin Thromb Hemost; 2004 Jun 02; 30(3):329-36. PubMed ID: 15282655
    [Abstract] [Full Text] [Related]

  • 8. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
    Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC, Mehran R, Pocock SJ, ACUITY Investigators.
    JAMA; 2007 Dec 05; 298(21):2497-506. PubMed ID: 18056903
    [Abstract] [Full Text] [Related]

  • 9. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
    Exaire JE, Butman SM, Ebrahimi R, Kleiman NS, Harrington RA, Schweiger MJ, Bittl JA, Wolski K, Topol EJ, Lincoff AM, REPLACE-2 Investigators.
    Am Heart J; 2006 Jul 05; 152(1):157-63. PubMed ID: 16824849
    [Abstract] [Full Text] [Related]

  • 10. Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions.
    Kao J, Lincoff AM, Topol EJ, Madrid A, J Price M, Sawhney N, Teirstein PS.
    Catheter Cardiovasc Interv; 2006 Sep 05; 68(3):352-6. PubMed ID: 16892428
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice.
    Kim LK, Wong SC, Minutello RM, Bergman G, Feldman DN.
    J Invasive Cardiol; 2010 Mar 05; 22(3):94-100. PubMed ID: 20197573
    [Abstract] [Full Text] [Related]

  • 12. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).
    Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, Henry T, Feit F, Topol EJ, REPLACE-2 Investigators.
    Am J Cardiol; 2005 Mar 01; 95(5):581-5. PubMed ID: 15721095
    [Abstract] [Full Text] [Related]

  • 13. Can bivalirudin and provisional GP IIb/IIIa blockade REPLACE heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention?
    Doggrell S.
    Expert Opin Pharmacother; 2003 Aug 01; 4(8):1431-3. PubMed ID: 12877649
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention.
    Summers KM, Holdford DA, Crouch MA.
    Pharmacotherapy; 2006 May 01; 26(5):609-18. PubMed ID: 16637790
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
    Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators.
    Lancet; 2007 Mar 17; 369(9565):907-19. PubMed ID: 17368152
    [Abstract] [Full Text] [Related]

  • 18. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R, Sardar P, Amin H, Swaminathan RV, Kim LK, Chatterjee S, Feldman DN.
    Am J Cardiol; 2014 Jul 15; 114(2):250-9. PubMed ID: 24890986
    [Abstract] [Full Text] [Related]

  • 19. Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
    Chacko M, Lincoff AM, Wolski KE, Cohen DJ, Bittl JA, Lansky AJ, Tsuchiya Y, Betriu A, Yen MH, Chew DP, Cho L, Topol EJ.
    Am Heart J; 2006 May 15; 151(5):1032.e1-7. PubMed ID: 16644331
    [Abstract] [Full Text] [Related]

  • 20. Planned versus provisional use of glycoprotein IIb/IIIa inhibitors in smokers undergoing percutaneous coronary intervention.
    Robertson JO, Lincoff AM, Wolski K, Topol EJ.
    Am J Cardiol; 2006 Jun 15; 97(12):1679-84. PubMed ID: 16765113
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.